

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 58599

Title: Efficacy and Safety of Anti-Hepatic Fibrosis Drugs

Reviewer's code: 03728255

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2020-08-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-08-12 05:09

Reviewer performed review: 2020-08-21 16:05

Review time: 9 Days and 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Dear editor I am very glad to review the manuscript entitled "Efficacy and Safety of Anti- Hepatic Fibrosis Drugs", which summarized the current anti-fibrotic drugs well. I have learned a lot from this review. However, I have some questions listed below. 1. NAFLD has been renamed as metabolic associated fatty liver diseases (MAFLD), which is pointed out in Gastroenterology. So you may correct the name of "NAFLD". 2. UDCA to PBC, Adefovir to HBV liver disease and Corticosteroid to autoimmune hepatitis are specific targeted hepatic insult for hepatitis, which may not be classified as anti-fibrotic drugs. 3. It is reported that angiotensin II antagonists improve myocardial remodeling. More evidences should be listed as it shows anti-fibrotic effect in clinics or basic experiment. 4. Some drugs were only listed in the tables such as Atorvastatin and Carvedilol, but not detailed described in the manuscript. We suggest that more new drugs expected to be effective should be introduced, which are not commonly used in the clinics.